RECENT DEVELOPMENTS IN THE PSYCHOPHARMACOLOGY OF SOCIAL PHOBIA

被引:0
|
作者
DENBOER, JA [1 ]
VANVLIET, IM [1 ]
WESTENBERG, HGM [1 ]
机构
[1] ACAD ZIEKENHUIS UTRECHT,AFD BIOL PSYCHIAT,UTRECHT,NETHERLANDS
关键词
SOCIAL PHOBIA; BENZODIAZEPINES; BETA-BLOCKING AGENTS; BROFAROMINE; MOCLOBEMIDE; FLUVOXAMINE; ORG-2766;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The last two decades have witnessed an upsurge in the interest in anxiety disorders. Much research effort has been dedicated to panic disorder and obsessive compulsive disorder. However, it is only very recently that we have begun to understand some of the basic principles about the psychopharmacology of social phobia. Drug classes so far studied include beta-blockers, non-selective and irreversible MAO-inhibitors (MAOI's) and benzodiazepinen. Beta-blockers appear to be of use in specific social phobias, like public speaking. There is considerable evidence suggesting that MAOI's are effective in reducing both social anxiety as well as social avoidance. A disadvantage of the conventional irreversible MAOI's is their risk for hypertensive crises when combined with dietary tyramine. So far only a small number of studies with selective MAOI-A inhibitors such as moclobemide and brofaromine have been conducted in social phobia, and the results indicate that both compounds are effective. Drugs exerting selective and specific actions on certain components of e.g. the serotonergic system can now be studied and it is hoped that the role of serotonin and other neuronal systems in social phobia can be elucidated. In order to gain more information about selective serotonergic drugs the first double blind placebo-controlled study with fluvoxamine in social phobia is here reported. Preliminary results indicate a reduction of social anxiety. Finally the role of peptides in the treatment of social phobia is critically reviewed. The MSH/ACTH analog Org 2766 was investigated inpatients suffering from social phobia. No anxiolytic effects of this peptide could be observed.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 50 条
  • [1] RECENT DEVELOPMENTS IN THE PSYCHOPHARMACOLOGY OF SOCIAL PHOBIA
    DENBOER, JA
    VANVLIET, IM
    WESTENBERG, HGM
    [J]. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 1995, 244 (06) : 309 - 316
  • [2] RECENT ADVANCES IN THE PSYCHOPHARMACOLOGY OF SOCIAL PHOBIA
    DENBOER, JA
    VANVLIET, IM
    WESTENBERG, HGM
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1994, 18 (04): : 625 - 645
  • [3] THE PSYCHOPHARMACOLOGY OF SOCIAL PHOBIA
    MARSHALL, JR
    [J]. BULLETIN OF THE MENNINGER CLINIC, 1992, 56 (02) : A42 - A49
  • [4] PSYCHOPHARMACOLOGY OF SOCIAL PHOBIA
    ONTIVEROS, A
    FONTAINE, R
    [J]. SALUD MENTAL, 1990, 13 (03) : 50 - 54
  • [5] Recent developments in child and adolescent social phobia.
    Chavira D.A.
    Stein M.B.
    [J]. Current Psychiatry Reports, 2000, 2 (4) : 347 - 352
  • [6] THE PSYCHOPHARMACOLOGY OF SOCIAL PHOBIA AND COMORBID DISORDERS
    ROSENBAUM, JF
    POLLOCK, RA
    [J]. BULLETIN OF THE MENNINGER CLINIC, 1994, 58 (02) : A67 - A83
  • [7] Recent developments in research and treatment for social phobia (social anxiety disorder)
    Cottraux, J
    [J]. CURRENT OPINION IN PSYCHIATRY, 2005, 18 (01) : 51 - 54
  • [8] Recent developments in geriatric psychopharmacology
    Aftab, Awais
    Lam, Jeffrey A.
    Liu, Fred
    Ghosh, Anjan
    Sajatovic, Martha
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (03) : 341 - 355
  • [9] Recent developments in the psychopharmacology of anxiety disorders
    Lydiard, RB
    BrawmanMintzer, O
    Ballenger, JC
    [J]. JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1996, 64 (04) : 660 - 668
  • [10] Recent Developments in Psychodermatology and Psychopharmacology for Delusional Patients
    Brownstone, Nicholas D.
    Koo, John
    [J]. CUTIS, 2021, 107 (01): : 5 - 6